Valentina Favorito

Bologna, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Clinical Outcomes and Predictors of Response to PD-(L)1 Blockade in Patients with NSCLC without Actionable Genomic Alterations Who Never Used Tobacco.

Clinical Outcomes and Predictors of Response to PD-(L)1 Blockade in Patients with NSCLC without Actionable Genomic Alterations Who Never Used Tobacco.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: December 17, 2025

NSCLC in Vulnerable and Special Populations: Toward Personalized Care.

NSCLC in Vulnerable and Special Populations: Toward Personalized Care.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: December 15, 2025

Immunotherapy beyond progression combined with platinum-based chemotherapy after primary resistance to first-line immunotherapy in patients with advanced NSCLC and PD-L1 ≥50.

Immunotherapy beyond progression combined with platinum-based chemotherapy after primary resistance to first-line immunotherapy in patients with advanced NSCLC and PD-L1 ≥50.

Journal: ESMO open

Published: August 26, 2025

Efficacy and Safety of TROP-2-Targeting Antibody-Drug Conjugate Treatment in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer: A Systematic Review and Pooled Analysis of Reconstructed Patient Data.

Efficacy and Safety of TROP-2-Targeting Antibody-Drug Conjugate Treatment in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer: A Systematic Review and Pooled Analysis of Reconstructed Patient Data.

Journal: Cancers

Published: April 27, 2025

Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRASG12C inhibitors.

Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRASG12C inhibitors.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: October 08, 2024

Development and validation of a new tool to estimate early mortality in patients with advanced cancer treated with immunotherapy.

Development and validation of a new tool to estimate early mortality in patients with advanced cancer treated with immunotherapy.

Journal: Cancer immunology, immunotherapy : CII

Published: June 13, 2024

Early monitoring of plasma KRAS G12C with digital PCR predicts antitumor response to immunotherapy or sotorasib in advanced NSCLC: A brief report.

Early monitoring of plasma KRAS G12C with digital PCR predicts antitumor response to immunotherapy or sotorasib in advanced NSCLC: A brief report.

Journal: The journal of liquid biopsy

Published: May 26, 2024

STK11 mutations correlate with poor prognosis for advanced NSCLC treated with first-line immunotherapy or chemo-immunotherapy according to KRAS, TP53, KEAP1, and SMARCA4 status.

STK11 mutations correlate with poor prognosis for advanced NSCLC treated with first-line immunotherapy or chemo-immunotherapy according to KRAS, TP53, KEAP1, and SMARCA4 status.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: May 17, 2024

Non-small cell lung cancer: an update on emerging EGFR-targeted therapies.

Non-small cell lung cancer: an update on emerging EGFR-targeted therapies.

Journal: Expert opinion on emerging drugs

Published: April 04, 2024

First-Generation Epidermal Growth Factor Receptor Inhibitors Plus Antiangiogenic Drugs Versus Third-Generation Epidermal Growth Factor Receptor Inhibitors in Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis.

First-Generation Epidermal Growth Factor Receptor Inhibitors Plus Antiangiogenic Drugs Versus Third-Generation Epidermal Growth Factor Receptor Inhibitors in Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis.

Journal: JCO precision oncology

Published: June 01, 2023

Resistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer.

Resistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer.

Journal: Current oncology reports

Published: May 30, 2023

Showing 1-11 of 11

Last Updated: 09/26/2026